gs1-01: "phase 3 study of pembrolizumab chemotherapy vs placebo chemotherapy as neoadjuvant..."
Published 1 year ago • 94 plays • Length 9:59Download video MP4
Download video MP3
Similar videos
-
9:41
gs1-02: "randomized, double-blind, phase 3 study of pembrolizumab chemotherapy vs placebo..."
-
3:49
keynote-522: neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs place...
-
4:54
keynote-522 updates: pembrolizumab plus neoadjuvant chemotherapy in early triple-negative breast...
-
5:25
neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early-...
-
4:20
keynote 522: pembrolizumab as neoadjuvant treatment for early tnbc
-
0:29
adjuvant treatment for high risk hr breast cancer | esmo 2023 breast cancer highlights
-
9:59
gs1-08: "cctgma.32, a phase iii randomized double-blind placebo controlled adjuvant trial of..."
-
1:46
exploratory analysis of keynote-522: efs after neoadjuvant pembro chemo vs chemo for early tnbc
-
38:22
adjuvant/neoadjuvant therapy for breast cancer: updates and molecular predictors of benefit
-
13:03
early tnbc - pembrolizumab chemotherapy: pathologic complete response in key subgroups
-
3:26
phase i/ii study of pembrolizumab binimetinib in unresectable locally advanced or metastatic tnbc
-
2:31
adjuvant/neoadjuvant therapy trials for breast cancer at sabcs 2021
-
1:03
remaining questions on the use of neoadjuvant pembrolizumab in early tnbc following keynote-522
-
0:55
neoadjuvant treatment approach for her2 positive breast cancer
-
10:37
gs4-09. quality of life results from olympia:
-
1:42
the case for neoadjuvant pembrolizumab in tnbc
-
4:17
keynote-522: efs sensitivity & subgroup analyses
-
29:20
educational sessions: "optimizing the management of early stage tnbc"